Search Results - "Immune-checkpoint inhibitors"

This result is not displayed to guests.
Login for full access.

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Cui X; Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China., Ruan M; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China., Li Y; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China., Yang C; Department of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China., Zhang J; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China., Jin R; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China., Wu D; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China., Sun W; National Center for Liver Cancer, The Naval Medical University, 800 Xiangyin Road, Shanghai, 200433, China. sunwen_sw@aliyun.com., Wang R; The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China. wangruoyu1213@126.com.

Journal Article , 2025

Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma.

Lin C; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Department of Liver Tumor Center, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhouda Road, Baiyun District, Guangzhou, 510515, China.; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Department of Oncology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhouda Road, Baiyun District, Guangzhou, Guangdong, 510515, China., Ren Y; University of Electronic Science and Technology of China, Chengdu, China.; Shensi Lab, Shenzhen Institute for Advanced Study, UESTC, Shenzhen, China.; The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China., Huang Y; Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Zhongshan Road II #58, Guangzhou, 510080, People's Republic of China., Li S; Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Zhongshan Road II #58, Guangzhou, 510080, People's Republic of China., Zhang J; Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Kang S; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Department of Liver Tumor Center, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhouda Road, Baiyun District, Guangzhou, 510515, China., Li S; Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., You C; Department of Oncology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhouda Road, Baiyun District, Guangzhou, Guangdong, 510515, China. ycx6026@126.com., Cao Q; Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Zhongshan Road II #58, Guangzhou, 510080, People's Republic of China. caoqhua@mail.sysu.edu.cn., Liu F; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Department of Liver Tumor Center, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhouda Road, Baiyun District, Guangzhou, 510515, China. liufang7250@163.com.; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. liufang7250@163.com.

Journal Article , 2025

Harnessing the human microbiome and its impact on immuno-oncology and nanotechnology for next-generation cancer therapies.

Das M; Department of Biomedical Science, Alagappa University, Karaikudi, 630003, India., Kiruthiga C; Department of Biomedical Science, Alagappa University, Karaikudi, 630003, India., Shafreen RB; Department of Biomedical Science, Alagappa University, Karaikudi, 630003, India., Nachammai K; Department of Biotechnology, Alagappa University, Science Campus, Karaikudi, Tamil Nadu, India., Selvaraj C; CsrDD Lab, Department of Microbiology, Dr. D. Y. Patil Medical College Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to Be University), Pimpri, Pune, 411018, India. Electronic address: drbioselva@gmail.com., Langeswaran K; Department of Biomedical Science, Alagappa University, Karaikudi, 630003, India; Department of Biotechnology, Alagappa University, Science Campus, Karaikudi, Tamil Nadu, India. Electronic address: dr.langeswaran@gmail.com.

Journal Article; Review , 2025

In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies.

Wang Y; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Sun Y; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Liu M; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Wang C; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Huang M; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Qiu J; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Yang N; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Zhang Y; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China., Liu H; State Key Laboratory of Crystal Materials, Shandong University, Jinan, 250100, P. R. China., Han L; Institute of Marine Science and Technology, Shandong University, Tsingdao, 266237, P. R. China. hanlin@sdu.edu.cn.; Shandong Engineering Research Center of Biomarker and Artificial Intelligence Application, Jinan, 250100, P. R. China. hanlin@sdu.edu.cn.

Journal Article , 2025

Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population.

Sayer M; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA., Agrawal P; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA., Ng DQ; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA., Kagramanov D; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA., Trudeau J; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA., Othy S; Department of Physiology & Biophysics, School of Medicine, University of California, Irvine, CA, USA., Acharya MM; Department of Anatomy & Neurobiology, School of Medicine, University of California, Irvine, CA, USA.; Department of Radiation Oncology, School of Medicine, University of California, Irvine, CA, USA., Chan A; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.

Journal Article , 2025

Comparison of the Immune Checkpoint InhibitorFree Survival Between Patients Who Completed and Those Who Discontinued ICI for Non-Small Cell Lung Cancer.

Nagai T; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Takase E; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Murakami E; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Sugimoto T; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Shibaki R; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Hayata A; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Shimizu T; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Nakanishi M; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Koh Y; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.; Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan., Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.; Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.

Journal Article; Comparative Study , 2025

The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study.

Amici M; Department of Dermatology, Rennes University Hospital, Rennes, France. Electronic address: mamici@ch-aix.fr., Neveu E; Research Department, CLCC Eugène Marquis, Rennes, France., Poizeau F; Department of Dermatology, Rennes University Hospital, Rennes, France; University of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France., Edeline J; Department of Medical Oncology, CLCC Eugène Marquis, Rennes, France., Lesimple T; Department of Medical Oncology, CLCC Eugène Marquis, Rennes, France., Oger E; Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, France., Danton G; Research Department, CLCC Eugène Marquis, Rennes, France., Dupuy A; Department of Dermatology, Rennes University Hospital, Rennes, France; Unité de Nutrition, CHU Rennes, INRAE, INSERM, Univ Rennes, Institut Nutrition Métabolismes et Cancer, NuMeCan, Rennes, France., Fouchard M; Department of Dermatology, Rennes University Hospital, Rennes, France.

Journal Article; Observational Study , 2025

Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus.

Zhong S; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Yi J; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Chen S; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Mo X; VIP Region, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Chen Q; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Guo W; Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China., Jiang X; Interventional Radiology Division, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China., Mu L; Department of Vascular Interventional Radiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, People's Republic of China., Hu Y; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Wang J; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Song Y; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Xu J; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Tan G; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Shi M; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Chen M; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China., Lyu N; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. lvning@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. lvning@sysucc.org.cn.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China. lvning@sysucc.org.cn., Zhao M; Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. zhaoming@mail.sysu.edu.cn.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. zhaoming@mail.sysu.edu.cn.; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China. zhaoming@mail.sysu.edu.cn.

Journal Article; Multicenter Study , 2025

Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung Cancer.

Lian J; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China., Sun L; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China., Zhang S; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China., Huang L; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China., Ma J; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. majt@sj-hospital.org., Han C; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. hanchengbo@sj-hospital.org.

Journal Article; Review , 2025

Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.

Trinconi Cunha M; Division of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wallace N; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Porceddu S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Ferrarotto R; Division of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Journal Article; Review , 2025

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.

Sugai M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Amino Y; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address: yoshiaki.amino@jfcr.or.jp., Fujishima S; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Nibuya K; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Iso H; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Ito M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Tsugitomi R; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Ariyasu R; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Uchibori K; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan., Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan.

Journal Article , 2025

Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.

Tanaka S; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Nozaki K; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Watanabe S; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: satoshi7@med.niigata-u.ac.jp., Yanagimura N; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Arita M; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Sato M; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Tanaka T; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Saida Y; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Goto Y; Department of Respiratory Medicine, Saiseikai Niigata Keno Core Hospital, Niigata, Japan., Kushiro K; Department of Respiratory Medicine, Kashiwazaki General Medical Center, Niigata, Japan., Fujisaki T; Department of Respiratory Medicine, Tachikawa General Hospital, Niigata, Japan., Sato K; Department of Respiratory Medicine, Joetsu General Hospital, Niigata, Japan., Ishikawa D; Department of Respiratory Medicine, Niigata Prefectural Central Hospital, Joetsu, Japan., Miyabayashi T; Department of Respiratory Medicine, Niigata City General Hospital, Niigata, Japan., Ichikawa K; Department of Respiratory Medicine, Saiseikai Niigata Hospital, Niigata, Japan., Ota T; Department of Respiratory Medicine, Niigata Prefectural Shibata Hospital, Niigata, Japan., Hayashi Y; Department of Respiratory Medicine, Nagaoka Central General Hospital, Niigata, Japan., Koyama K; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan., Ishida A; Department of Respiratory Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan., Kikuchi T; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Journal Article , 2025

Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma.

Ng KYY; Division of Population Health and Integrated Care, Singapore General Hospital, Singapore, Singapore.; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore., Teo AEK; Division of Internal Medicine, Singapore General Hospital, Singapore, Singapore., Tan SH; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore.; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore., Tan JJE; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tay DSH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lee AWX; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Ang AJS; Division of Internal Medicine, Singapore General Hospital, Singapore, Singapore., Wong LWJ; Division of Pediatrics, KK Women and Children's Hospital, Singapore, Singapore., Choo SP; Curie Oncology, Singapore, Singapore., Toh HC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore., Lee SY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore., Lee JJX; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore., Tai DW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore.

Journal Article , 2025

Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy.

Hossain SM; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Gimenez G; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Stockwell P; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Weeks R; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Almomani S; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Jones GT; Department of Surgical Sciences, University of Otago, Dunedin, New Zealand., Ratajska M; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand; Department of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland., Shuen M; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Bhat B; Department of Surgical Sciences, University of Otago, Dunedin, New Zealand., Ryś J; Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland., Cybulska-Stopa B; Department of Clinical Oncology, Lower Silesian Oncology Center, Pulmonology and Hematology, Wroclaw, Poland; Department of Hematology and Oncology, Faculty of Medicine, Wroclaw University of Science and Technology, Poland., Harazin-Lechowska A; Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland., Rodger E; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Jackson C; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Chatterjee A; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand., Eccles MR; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level 2, 3A Symonds Street, Auckland, New Zealand. Electronic address: michael.eccles@otago.ac.nz.

Journal Article , 2025

NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.

Gao Y; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Zuo L; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Zheng Y; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Sun K; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Gao Y; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Xu X; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Li Z; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China., Zuo D; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China. zuodaiying@163.com.

Journal Article , 2025

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.

Xu S; Department of Interventional Therapy, The First Hospital of Jilin University, 1# Xinmin St, Changchun, 130021, China., Zheng R; Department of Interventional Therapy, The First Hospital of Jilin University, 1# Xinmin St, Changchun, 130021, China., Sun C; Clinical Collage, The First Hospital of Jilin University, 1# Xinmin St, Changchun, 130021, China., Sa R; Department of Nuclear Medicine, The First Hospital of Jilin University, 1# Xinmin St, Changchun, 130021, China. sari@jlu.edu.cn.

Journal Article , 2025

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes.

Yang H; Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.; Laboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China., Yu S; Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.; Laboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China., Ge H; Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.; Laboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Journal Article; Review , 2025

Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Zhou X; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China., Xu Y; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China., Ying Y; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China., Chen R; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China., Wang Z; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China., Lv X; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.

Journal Article; Systematic Review; Meta-Analysis , 2025

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs.

Maekawa N; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Japan., Konnai S; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Japan.; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Veterinary Research Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Watari K; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Takeuchi H; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan., Nakanishi T; Department of Chemistry and Bioengineering, Division of Science and Engineering for Materials, Chemistry and Biology, Graduate School of Engineering, Osaka Metropolitan University, Osaka, Japan., Tachibana T; Department of Chemistry and Bioengineering, Division of Science and Engineering for Materials, Chemistry and Biology, Graduate School of Engineering, Osaka Metropolitan University, Osaka, Japan., Hosoya K; Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Japan.; Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Kim S; Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Japan.; Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Kinoshita R; Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Japan.; Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Owaki R; Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Yokokawa M; Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Kagawa Y; North Lab, Sapporo, Japan., Takagi S; Department of Veterinary Surgery 1, School of Veterinary Medicine, Azabu University, Sagamihara, Japan., Deguchi T; Companion Animal Internal Medicine, Department of Companion Animal Clinical Sciences, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Japan., Ohta H; Companion Animal Internal Medicine, Department of Companion Animal Clinical Sciences, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Japan., Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan., Yamamoto S; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Fuso Pharmaceutical Industries, Ltd., Osaka, Japan., Yamamoto K; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Fuso Pharmaceutical Industries, Ltd., Osaka, Japan., Suzuki Y; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Bioresources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan., Okagawa T; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan., Murata S; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Veterinary Research Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Ohashi K; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.; Veterinary Research Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; International Affairs Office, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.

Journal Article , 2025